Literature DB >> 19752011

Device diagnostics and long-term clinical outcome in patients receiving cardiac resynchronization therapy.

Jagmeet P Singh1, Lawrence S Rosenthal, Patrick M Hranitzky, Kellie Chase Berg, Christopher M Mullin, Lisa Thackeray, Andrew Kaplan.   

Abstract

AIMS: This retrospective analysis sought to develop and validate a model using the measured diagnostic variables in cardiac resynchronization therapy (CRT) devices to predict mortality. METHODS AND
RESULTS: Data used in this analysis came from two CRT studies: Cardiac Resynchronization Therapy Registry Evaluating Patient Response with RENEWAL Family Devices (CRT RENEWAL) (n = 436) and Heart Failure-Heart Rate Variability (HF-HRV) (n = 838). Patients from CRT RENEWAL were used to create a model for risk of death using logistic regression and to create a scoring system that could be used to predict mortality. Results of both the logistic regression and the clinical risk score were validated in a cohort of patients from the HF-HRV study. Diagnostics significantly improved over time post-CRT implant (all P < 0.001) and were correlated with a trend of decreased risk of death. The regression model classified CRT RENEWAL patients into low (2.8%), moderate (6.9%), and high (13.8%) risk of death based on tertiles of their model predicted risk. The clinical risk score classified CRT RENEWAL patients into low (2.8%), moderate (10.1%), and high (13.4%) risk of death based on tertiles of their score. When both the regression model and the clinical risk score were applied to the HF-HRV study, each was able to classify patients into appropriate levels of risk.
CONCLUSION: Device diagnostics may be used to create models that predict the risk of death.

Entities:  

Mesh:

Year:  2009        PMID: 19752011     DOI: 10.1093/europace/eup250

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  7 in total

1.  Increasing knowledge and changing views in cardiac resynchronization therapy.

Authors:  Laszlo Buga; John G F Cleland
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

2.  Multidisciplinary care of patients receiving cardiac resynchronization therapy is associated with improved clinical outcomes.

Authors:  Robert K Altman; Kimberly A Parks; Christopher L Schlett; Mary Orencole; Mi-Young Park; Quynh A Truong; Peerawut Deeprasertkul; Stephanie A Moore; Conor D Barrett; Gregory D Lewis; Saumya Das; Gaurav A Upadhyay; E Kevin Heist; Michael H Picard; Jagmeet P Singh
Journal:  Eur Heart J       Date:  2012-05-21       Impact factor: 29.983

Review 3.  How to improve outcomes: should we put more emphasis on programming and medical care and less on patient selection?

Authors:  Laszlo Buga
Journal:  Heart Fail Rev       Date:  2012-11       Impact factor: 4.214

Review 4.  Past, present, and future of CRT.

Authors:  Angelo Auricchio; François Regoli
Journal:  Heart Fail Rev       Date:  2011-05       Impact factor: 4.214

Review 5.  Accelerometer-assessed physical behavior and the association with clinical outcomes in implantable cardioverter-defibrillator recipients: A systematic review.

Authors:  Maarten Z H Kolk; Diana M Frodi; Tariq O Andersen; Joss Langford; Soeren Z Diederichsen; Jesper H Svendsen; Hanno L Tan; Reinoud E Knops; Fleur V Y Tjong
Journal:  Cardiovasc Digit Health J       Date:  2021-11-24

6.  Development and validation of an integrated diagnostic algorithm derived from parameters monitored in implantable devices for identifying patients at risk for heart failure hospitalization in an ambulatory setting.

Authors:  Martin R Cowie; Shantanu Sarkar; Jodi Koehler; David J Whellan; George H Crossley; Wai Hong Wilson Tang; William T Abraham; Vinod Sharma; Massimo Santini
Journal:  Eur Heart J       Date:  2013-03-19       Impact factor: 29.983

7.  Measuring Physical Activity With Implanted Cardiac Devices: A Systematic Review.

Authors:  Lindsey Rosman; Rachel Lampert; Samuel F Sears; Matthew M Burg
Journal:  J Am Heart Assoc       Date:  2018-05-17       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.